Ratio Therapeutics Inc., a pharmaceutical company using new technology to develop radiopharmaceuticals for cancer treatment and monitoring, has entered into an agreement with the Medical Innovation Technology Management (MIT) division of Salt Lake City’s Wasatch Group to partner and construct a radiopharmaceutical research and manufacturing facility in Utah.
The Boston firm expects the plant to be fully operational in the second half of 2027.
The 65,000-square-foot manufacturing facility will support vertical integration of Ratio’s current and future pipeline of next-generation radiopharmaceuticals, with the capacity to efficiently scale manufacturing for future commercial needs as Ratio advances its Please log in to see the rest of this story.
